 |
Prospector
Profile
2-25-001
|
| |
| Accentia Biopharmaceuticals, Inc. |
NAICS |
325412 |
| 324 South Hyde Park Ave., Suite 350
Tampa, FL 33606 |
Description |
Pharmaceuticals Mfg. |
| (813) 864-2554 |
Employees |
140 |
| http://www.accentia.net/ |
Revenue |
(mil) |
18.2800 |
| |
Income |
(mil) |
-76.0100 |
| |
Assets |
(mil) |
33.0500 |
| |
Liability |
(mil) |
93.1700 |
| |
(for the year ended 2007-09-30) |
| |
|
Category:
Loss/Deficit
|
| |
|
Event:
Accentia Biopharmaceuticals, Inc.'s first quarter net loss, on a fully consolidated basis, including Biovest International Inc., was $24.8 million, compared to $30.6 million reported for the same three month period in fiscal 2007. On a fully consolidated basis, net sales for the three months ended December 31, 2007, were $4.3 million, compared with $5.9 million for the same period ended December 31, 2006. The Company's consolidated balance sheet at December 31, 2007, showed $37.8 million in total assets, $107.5 million in total liabilities, and $4.9 million in non-controlling interest in variable interest entities, resulting in a $74.6 million total stockholders' deficit. At December 31, 2007, the company's consolidated balance sheet also showed strained liquidity with $18.7 million in total current assets available to pay $76.7 million in total current liabilities.
|
| |
|
Intellectual Property:
The Company's rights to SinuNase(TM) are based on a license agreement with Mayo Foundation for Medical Education and Research. The license gives the Company the exclusive worldwide right to commercialize the patented chronic rhinosinusitis (CRS) treatment method using the antifungal amphotericin B. The Company also holds an exclusive license to market and sell products made from amphotericin B based on Mayo's patented treatment method for CRS. Although amphotericin B has not been approved by the FDA for the treatment of CRS, a number of physicians currently prescribe a compounded formulation of amphotericin B solution for their CRS patients. [SEC Filing 10-K 12-28-07]
|
| |
|
Description:
Accentia Biopharmaceuticals, Inc., develops and commercializes late-stage clinical products for respiratory disease and oncology.
|
| |
|
Officers:
Francis E. O'Donnell, Jr. (Chair & CEO); Steven R. Arikian (Pres., COO & Dir.); Alan M. Pearce (CFO)
|
| |
|
Auditor:
Aidman Piser & Company PA
|
| |
|
Securities:
Common Stock Symbol ABPI; NasdaqGM; 43,180,576 common shares outstanding as of January 31, 2008.
|
| |
| |
| |
| return to main page |
|
|
